Inflammation in ischemic stroke subtypes

Current Pharmaceutical Design

Volumn 18, Issue 28, 2012, Pages 4289-4310

  Tuttolomondo, Antonino ^a   Di Raimondo, Domenico ^a   Pecoraro, Rosaria ^a   Arnao, Valentina ^a   Pinto, Antonio ^a   Licata, Giuseppe ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cytokines; Inflammation; Stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; HEPARINOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW MOLECULAR WEIGHT HEPARIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BRAIN DAMAGE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; DEEP VEIN THROMBOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; LACUNAR STROKE; NEUROIMAGING; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; STROKE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CYTOKINES; HUMANS; INFLAMMATION; INTERLEUKIN-6; OUTCOME ASSESSMENT (HEALTH CARE); SEVERITY OF ILLNESS INDEX; STROKE;

EID: 84866398504     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802481200     Document Type: Article

References (191)

1. Caplan, LR. Caplan's stroke, a clinical approach, 3rd ed, Butterworth- Heinemann, Boston 2000; p. 17.
2. Vemmos KN, Bots ML, Tsibouris PK, et al. Stroke incidence and case fatality in southern Greece: the Arcadia stroke registry. Stroke 1999; 30: 363-370.
3. Kolominsky-Rabas PL, Sarti C, Heuschmann PU, et al. A prospective community-based study of stroke in Germany: the Erlangen Stroke Project. Stroke 1998; 29: 2501-2506.
4. Carolei A, Marini C, Di Napoli M, et al. High stroke incidence in the prospective community-based L'Aquila registry (1994-1998): first year's results. Stroke 1997; 28: 2500-2506.
5. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through. Stroke 1989 1996; 27: 373-380.
6. Feigin VL, Wiebers DO, Whisnant JP, O'Fallon WM. Stroke incidence and 30-day case-fatality rates in Novosibirsk, Russia, 1982 through 1992. Stroke 1995; 26: 924-929.
7. Sarti C, Tuomilehto J, Sivenius J, et al. Declining trends in incidence, case-fatality and mortality of stroke in three geographic areas of Finland during 1983-1989: results from the FINMONICA stroke register. J Clin Epidemiol 1994; 47: 1259-1269.
8. Bonita R, Anderson CS, Broad JB, Jamrozik KD, Stewart-Wynne EG, Anderson NE. Stroke incidence and case fatality in Australasia: a comparison of the Auckland and Perth population-based stroke registers. Stroke 1994; 25: 552-557.
9. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinical subtypes of cerebral infarction. Lancet 1991; 337: 1521-1526.
10. Sacco SE, Whisnant JP, Broderick JP, Philips SJ, O'Fallon WM. Epidemiological characteristics of lacunar infarcts in a population. Stroke 1991; 22: 1236-1241.
11. Koller RL: Recurrent embolic cerebral infarction and anticoagulation. Neurology 1982; 32: 283-285.
12. Sage JI, van Uitert RL. Risk of recurrent stroke in atrial fibrillation and nonvalvular heart disease. Stroke 1983; 14: 668-676.
13. Caplan LR, Hier DB, D'Cruz I. Cerebral embolism in the Michael Reese Stroke Registry. Stroke 1983; 14: 530-536.
14. Bogousslavsky J, Van Melle G, Regli F: The Lausanne Stroke Registry: Analysis of 1, 000 consecutive patients with first stroke. Stroke 1988; 19: 1083-1092.
15. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24(1): 35-41.
16. Bogousslavsky J, Van Melle G, Regli F: The Lausanne Stroke Registry: Analysis of 1, 000 consecutive patients with first stroke. Stroke 1988; 19: 1083-1092.
17. Mohr JP, Caplan LR, Melski JW, et al. The Harvard Cooperative Stroke Registry: A prospective registry. Neurology 1978; 28: 754-762.
18. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 2001 1; 32(12): 2735-2740.
19. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 1999; 30(12): 2513-2516.
20. Giacomini MK. Gender and ethnic differences in hospital-based procedure utilization in California. Arch Intern Med 1996; 156: 1217-1224.
21. Gillum RF. Epidemiology of carotid endarterectomy and cerebral arteriography in the United States. Stroke 1995; 26: 1724-1728.
22. Woo D, Gebel J, Miller R, et al. Incidence rates of first-ever ischemic stroke subtypes among blacks: a population-based study. Stroke 1999; 30: 2517-2522.
23. Gorelick PB. Cerebrovascular disease in African Americans. Stroke 1998; 29: 2656-2664
24. Wityk RJ, Lehman D, Klag M, Coresh J, Ahn H, Litt B. Race and sex differences in the distribution of cerebral atherosclerosis. Stroke 1996; 27: 1974-1980.
25. Mort EA, Weissman JS, Epstein AM. Physician discretion and racial variation in the use of surgical procedures. Arch Intern Med 1994; 154: 761-767.
26. Carlisle DM, Valdez RB, Shapiro MF, Brook RH. Geographic variation in rates of selected surgical procedures within Los Angeles County. Health Serv Res 1995; 30: 27-42.
27. Oddone EZ, Horner RD, Monger ME, Matchar DB. Racial variations in the rates of carotid angiography and endarterectomy in patients with stroke and transient ischemic attack. Arch Intern Med 1993; 153: 2781-2786.
28. Horner RD, Oddone EZ, Matchar DB. Theories explaining racial differences in the utilization of diagnostic and therapeutic procedures for cerebrovascular disease. Milbank Q 1995; 73: 443-462.
29. Lavados PM, Sacks C, Prina L, et al. Incidence, case-fatality rate, and prognosis of ischaemic stroke subtypes in a predominantly Hispanic-Mestizo population in Iquique, Chile (PISCIS project): a community-based incidence study. Lancet Neurol 2007; 6(2): 140-148.
30. Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 2009; 40: e380-e389.
31. Castellanos M, Leira R, Tejada J, Gil-Peralta A, et al. Predictors of good outcome in medium to large spontaneous supratentorial intracerebral haemorrhages. J Neurol Neurosurg Psychiatry 2005; 76: 691-695.
32. Castillo J, Davalos A, Alvarez-Sabin J, et al. Molecular signatures of brain injury after intracerebral hemorrhage. Neurology 2002; 58: 624-629.
33. Drake C, Boutin H, Jones MS, et al. Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav Immun 2011; 25(6): 1113-1122.
34. Brea D, Blanco M, Ramos-Cabrer P, et al. Toll-like receptors 2 and 4 in ischemic stroke: outcome and therapeutic values. J Cereb Blood Flow Metab 2011; 31(6): 1424-1431.
35. Youn CS, Choi SP, Kim SH, et al. Serum highly selective Creactive protein concentration is associated with the volume of ischemic tissue in acute ischemic stroke. Am J Emerg Med 2010 Dec 13. [Epub ahead of print]
36. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22: 391-397.
37. Arvin B, Neville LF, Barone FC, Feuerstein GZ. The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev 1996; 20: 445-452.
38. Stoll G, Jander S, Schroeter M. Inflammation and glial responses in ischemic brain lesions. Prog Neurobiol 1998; 56: 149-171.
39. Ramsay SC, Weiller C, Myers R, Cremer JE, Luthra SK, Lammertsma AA, Frackowiak RS: Monitoring by PET of macrophage accumulation in brain after ischaemic stroke. Lancet 1992; 339: 1054-1055.
40. Enblad P, Frykholm P, Valtysson J, et al. Middle cerebral artery occlusion and reperfusion in primates monitored by microdialysis and sequential positron emission tomography. Stroke 2001; 2: 1574-1580.
41. Walberer M, Rueger MA, Simard ML, et al. Dynamics of neuroinflammation in the macrosphere model of arterio-arterial embolic focal ischemia: an approximation to human stroke patterns Exp Transl Stroke Med 2010; 20; 2(1): 22.
42. Buck BH, Liebeskind DS, Saver JL, et al. Early neutrophilia is associated with volume of ischemic tissue in acute stroke. Stroke 2008; 39(2): 355-360.
43. Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992; 23, 1367-1379.
44. Yamasaki Y, Matsuo Y, Matsuura N, Onodera H, Itoyama Y, Kogure K. Transient increase of cytokine-induced neutrophil chemoattractant, a member of the interleu-kin-8 family, in ischemic brain areas after focal ischemia in rats. Stroke 1995; 26, 318-322.
45. Jander S, Pohl J, D'Urso D, Gillen C, Stoll G. Time course and localization of interleukin-10 mRNA and protein expression in autoimmune inflammation of the rat central nervous system. Am J Pathol 1998; 152: 975-982.
46. Stoll G, Trapp BD, Grin JW. Macrophage function during Wallerian degeneration of the rat optic nerve: clearance of degenerating myelin and Ia expression. J Neurosci 1989; 9: 2327-2335.
47. Chung IL, Benveniste EN. Tumor necrosis factor prcduction by astrocytes: Induction by lipopolysacharide, IFN-y, and IL- I p. J Immunol 1990; 144: 2999-3007.
48. Aloisi F, Car F, Borsellino G, et al. Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-l/l and tumor necrosis factor-a. J Immunol 1992; 149: 2358-2366.
49. Frei K, Nohava K, Malipiero UV, Schwerdel C, Fontana A. Production of macrophage colony-stimulating factor by astrocytes and brain macrophages. J. Neuroimmunol 1992; 40: 189-198.
50. Wang YY, Lin SY, Chuang YH, Chen CJ, Tung KC, Sheu WH. Adipose proinflammatory cytokine expression through sympathetic system is associated with hyperglycemia and insulin resistance in a rat ischemic stroke model. Am J Physiol Endocrinol Metab 2011; 300(1): E155-E163.
51. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol 2006; 184: 53-68.
52. Barone FC, Schmidt DB, Hillegass LM, et al. Reperfusion increases neutrophils and leukotriene B4 receptor binding in rat focal ischemia. Stroke 1992; 23: 1337-1347.
53. Barone FC, Hillegass LM, Price WJ, et al. Polymorphonuclear leukocyte infiltration into cerebral focal ischemic tissue: myeloperoxidase activity assay and histologic verification. J Neurosci Res 1991; 29: 336-345.
54. Barone FC. Ischemic stroke intervention requires mixed cellular protection of the penumbra. Curr Opin Investig Drugs 2009; 10:220-223.
55. Beamer NB, Coull BM, Clark WM, et al. Focal cerebral ischemia in the rat: temporal profile of neutrophil responses. Neurosci. Res. Commun 1992; 11: 179-186
56. Qamirani E, Ren Y, Kuo L, Hein TW. C-reactive protein inhibits endothelium-dependent NO-mediated dilation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase. Arterioscler Thromb Vasc Biol 2005; 25(5): 995-1001.
57. Kuhlmann CR, Librizzi L, Closhen D, et al. Mechanisms of Creactive protein-induced blood-brain barrier disruption. Stroke 2009; 40(4): 1458-1466.
58. Welsh P, Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc Dis 2009; 27(3): 247-253.
59. Shantikumar S, Grant PJ, Catto AJ, Bamford JM, Carter AM. Elevated C-reactive protein and long-term mortality after ischaemic stroke: relationship with markers of endothelial cell and platelet activation. Stroke 2009; 40(3): 977-979.
60. Ryu SR, Choi IS, Bian RX, Kim JH, Han JY, Lee SG. The effect of C-reactive protein on functional outcome in ischemic stroke patients. Int J Neurosci 2009; 119(3): 336.
61. Idicula TT, Brogger J, Naess H, Waje-Andreassen U, Thomassen L. Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the 'Bergen stroke study'. BMC Neurol 2009; 9: 18.
62. Minami M, Kuraishi Y, Yabuuchi K, Yamazaki K, Satoh M. Induction of interleukin-lb mRNA in rat brain after transient forebrain ischaemia. J Neurochem 1992; 58: 390-392.
63. Buttini H, Sauter M, Boddeke A, HWGM. Induction of interleukmb mRNA after focal cerebra1 ischaemia in the rat. Mol Brain Res 1994; 126-134.
64. Liu T, McDonnell PC, Young PR, et al. Interleukin-1 expression in ischemic rat cortex. Stroke 1993; 24: 1746-1752
65. Liu T, Young PR, McDonnell PC, White RF, Barone FC, Feuerstein GZ. Cytokine-induced neutrophil chemoattractant mRNA expressed in cerebral hernia. Neurosc. Lett 1993; 164: 125-128.
66. Liu T, Clark RK, McConnell PC, et al. Upregulation of intercellular adhesion molecules-l (ICAM-1) expression in primary cultures of human microvessel endothelial cells by cytokines and lipopolysaccharide. J. Neuroimmunol 1992; 39: 1 1-21.
67. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL. Anti-TNF-alpha therapies: the next generation. Nat Rev Drug Discov 2003; 2(9): 736-734.
68. Tarkowski E, Rosengren L, Blomstrand C, et al. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995; 26: 1393-1398.
69. Matbiesen T, Anderson B, Loftenius A, von Holst H. Increased interleukin-6 levels in cerebrospinal fluid foilowing subarachnoid hemorrhage. J Neurosurg 1993; 78: 562-567.
70. McClain CJ, Cohen, D, Phyllips R, Ott L, Young B. Increased plasma and ventricular interleukm-6 levels in head injured patients. J Lab Clin Med 1991; 118: 225-230.
71. Liu T, Clark RK, McDonnell PC, et al. Tumor necrosis factoralpha expression in ischemic neurons. Stroke 1994; 25(7): 1481-1488.
72. Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998; 29(10): 2189-2195.
73. Robertson J, Beaulieu JM, Doroudchi MM, Durham HD, Julien JP, Mushynski WE. Apoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor-alpha. J Cell Biol 2001 15; 155(2): 217-226
74. Martin-Villalba A, Hahne M, Kleber S, et al. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ 2001; 8(7): 679-686.
75. Nawashiro H, Tasaki K, Ruetzler CA, Hallenbeck JM. TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J Cereb Blood Flow Metab 1997; 17(5): 483-490.
76. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16: 27-55.
77. Zhang W, Smith C, Howlett C, Stanimirovic D. Inflammatory activation of human brain endothelial cells by hypoxic astrocytes in vitro is mediated by IL-1beta. J Cereb Blood Flow Metab 2000; 20(6): 967-978.
78. Nomura Y, Fujii F, Sato C, Nemoto M, Tamura M. Exchange transfusion with fluorocarbon for studying synaptically evoked optical signal in rat cortex. Brain Res Brain Res Protoc 2000; 5(1): 10-15.
79. Tarkowski E, Rosengren L, Blomstrand C, et al. Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol. 1997; 110(3): 492-499.
80. Kostulas N, Kivisäkk P, Huang Y, Matusevicius D, Kostulas V. Link HIschemic stroke is associated with a systemic increase of blood mononuclear cells expressing interleukin-8 mRNA. Stroke 1998; 29(2): 462-466.
81. Vila N, Filella X, Deulofeu R, Ascaso C, Abellana R, Chamorro A. Cytokine-induced inflammation and long-term stroke functional outcome. J Neurol Sci 1999; 162(2): 185-188.
82. Smith CJ, Emsley HC, Vail A, et al. Variability of the systemic acute phase response after ischemic stroke. J Neurol Sci 2006; 251: 77-81.
83. Hallenbeck JM. The many faces of tumor necrosis factor in stroke. Nat Med 2002; 8: 1363-1368.
84. Fassbender K, Rossol S, Kammer T, et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci 1994; 22: 135-139.
85. Beamer NB, Coull BM, Clark WM, Briley DP, Wynn M, Sexton G. Persistent inflammatory response in stroke survivors. Neurology 1997; 50: 1722-1728.
86. Tarkowski E, Rosengren L, Blomstrand C, Jensen C, Ekholm S, Tarkowski A. Intrathecal expression of proteins regulating apoptosis in acute stroke. Stroke 1999; 30(2): 321-327.
87. Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000; 31: 2325-2329.
88. Frenkel D, Huang Z, Maron R, Koldzic DN, Moskowitz MA, Weiner HL. Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J Neurol Sci 2005; 233: 125-132.
89. Morita Y, Takizawa S, Kamiguchi H, Uesugi T, Kawada H, Takagi S. Administration of hematopoietic cytokines increases the expression of anti-inflammatory cytokine (IL-10) mRNA in the subacute phase after stroke. Neurosci Res 2007; 58: 356-360.
90. Kes VB, Simundic AM, Nikolac N, Topic E, Demarin V. Proinflammatory and anti-inflammatory cytokines in acute ischemic stroke and their relation to early neurological deficit and stroke out come. Clinical Biochemistry 2008; 41 1330-1334.
91. Castellanos M, Castillo J, García MM, et al. Inflammationmediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke 2002; 33(4): 982-987.
92. Liu T, Clark RK, McDonnel PC, et al. Tumor necrosis factor-_ in ischemic neurons. Stroke 1994; 25: 1481-1488.
93. Feuerstein GZ, Liu T, Barone FC. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-α. Cerebrovasc Brain Metab Rev 1994; 6: 341-360.
94. Bitsch A, Klene W, Murtada L, Prange H, Rieckmann P. A longitudinal prospective study of soluble adhesion molecules in acute stroke. Stroke 1998; 29: 2129-2135.
95. Fassbender K, Mössner R, Motsch L, Kischka U, Grau A, Hennerici M. Circulating selectin- and immunoglobulin-type adhesion molecules in acute ischemic stroke. Stroke 1995; 26: 1361-1364.
96. Serena J, Leira R, Castillo J, Pumar JM, Castellanos M, Dávalos A. Neurological deterioration in acute lacunar infarctions: the role of excitatory and inhibitory neurotransmitters. Stroke 2001; 32: 1154-1161.
97. Greenamyre JT, Porter RHP. Anatomy and physiology of glutamate in the CNS. Neurology 1994; 44: S7-13.
98. Sotgiu S, Zanda B, Marchetti B, et al. Inflammatory biomarkers in blood of patients with acute brain ischemia. Eur J Neurol 2006; 13(5): 505-513.
99. Stoll G, Jander S, Schroeter M. Inflammation and glial response to ischemic brain lesions. Prog. Neurobiol 1998; 56, 149-171.
100. Feuerstein GZ, Wang X, Barone FC. Inflammatory mediators and brain injury: the role of cytokines and chemokines in stroke and CNS diseases. In: Ginsberg, MD, Bogousslavsky, J (Eds.), Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management, vol. 1. Blackwell Science, Boston, Mass 1988; pp. 507-531 (10).
101. Yamasaki Y, Matsuura N, Shozuhara H, Onodera H, Itoyama Y, Kogure K. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke 1995; 26: 676-681.
102. Licata G, Tuttolomondo A, Corrao S, et al. Immunoinflammatory activation during the acute phase of lacunar and non-lacunar ischemic stroke: association with time of onset and diabetic state. Int J Immunopathol. Pharmacol 2006; 9 (3): 639-646.
103. Del Zoppo GI, Ginis JM, Hallenback C, Iadecola X, Wang GZ. Feuerstein. Inflammation and stroke: putative role for cytokines, adhesion molecules and i-NOS in brain response to ischemia. Brain Pathol 2000; 10: 95.
104. Conolly ES Jr, Winfree CJ, Springer TA, et al. Cerebral protection in homozygous null ICAM-1 after middle cerebral artery occlusion: role of neutrophil adhesion in the pathogenesis of stroke. J. Clin. Invest 1996; 7: 209.
105. Buttini MA. Sauter and H. W. Boddeke. Induction of interleukin-1 beta mRNA after focal cerebral ischaemia in the rat. Mol. Brain Res 1994; 23: 126.
106. Eriksson CAM, Van Dam PJ, Lucassen JG, Bol Winblad B, Schultzberg M. Immunohistochemical localization of interleukin-1beta, interleukin-1 receptor antagonist and interleukin-1beta converting enzyme/caspase-1 in the rat brain after peripheral administration of kainic acid. Neuroscience 1999; 93: 915.
107. Shalaby MR, Aggarwal BB. Rinderknechte. Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factor. J Immunol 1985; 135: 2069.
108. Dong JS, Fujii D, Goto T, et al. Increased expression of plasminogen activator inhibitor-1 by mediators of the acute phase response: a potential progenitor of vasculopathy in Hypertensives. Hypertens. Res 2003; 26: 723.
109. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998; 47: 290.
110. Pinto A, Tuttolomondo A, Di Raimondo D, Fernandez P. and Licata G. Cerebrovascular risk factors and clinical classification of strokes. Semin. Vasc. Med 2004; 4: 287.
111. Tuttolomondo A, Pinto A, Di Raimondo D, Fernandez P, Licata G. Stroke patterns, etiology and prognosis in patients with diabetes mellitus. Neurology 2005; 64: 581.
112. Hillen TC, Coshall K, Tilling A, Rudd R, Mc-Govern, Wolfe C. Cause of stroke recurrence is multifactorial. Patterns, risk factors and outcome of stroke recurrence in the South London, Stroke Register. Stroke 2003; 34: 1457.
113. Peress NS, Kane WC. Central nervous system findings in tenth decade autopsypopulation. Prog. Brain Res 1973; 40: 473.
114. Okada YBR, Copeland E, Mori MM, Tung WS. Thomas and G. J. Del Zoppo 1994. P-Selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke 1994; 25: 202.
115. Flex A, Gaetani E, Papaleo P, et al. Pola. Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke 2004; 35: 2270.
116. Libby P, Ridker PM, Maseri A, Inflammation and atherosclerosis. Circulation 2002; 105(9): 1135-1143.
117. Schneider DJ, Ricci MA, Taatjes DJ, et al. Changes in arterial expression of fibrinolytic system proteins in atherogenesis. Arterioscler. Thromb. Vasc. Biol 1997; 17: 294-3301.
118. Castellanos M, Castillo J, García M, et al. Inflammation-mediated damage in progressing lacunar infarctions. a potential therapeutic target. Stroke 2002; 33: 982-987.
119. Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000; 31: 2325-2329.
120. Tuttolomondo A, Di Sciacca R, Di Raimondo D, et al. Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes: relationship with TOAST subtype, outcome and infarct site. J Neuroimmunol 2009; 30: 84-89.
121. Rothwell NJ, Loddick SA, Stroemer P. Interleukins and cerebral ischaemia. Int Rev Neurobiol 1997; 40: 281-298
122. Tarkowski E, Rosengren L, Blomstrand C, et al. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995; 26 (8): 1393-1398.
123. Intiso D, Zarrelli MM, Lagioia G, et al. Tumor necrosis factor alphaserum levels and inflammatory response in acute ischemic stroke patients. Neurol Sci 2004; 24 (6): 390-396.
124. Hart RG, Albers G, Koudstaal P. Cardioembolic stroke. In: Ginsberg, M, Management. Blackwell Science, pp 1998: 1392-1429.
125. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27 (10): 1760-1764.
126. Fassbender K, Rossol S, Kammer T, et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain-damage and outcome of disease. J Neurol Sci 1994; 122: 135-139.
127. Carlstedt F, Lind L, Lindahl B. Proinflammatory cytokines, measured in a mixed population on arrival in the emergency department, are related to mortality and severity of disease. J Intern Med 1997; 61-365.
128. Wodarz, R. Atershed infarctions and computed tomography: a topographical study in cases with stenosis or occlusion of the carotid artery. Neuroradiology 1980; 5-248.
129. Ringelstein EB, Zeumer H, Angelou D. The pathogenesis of strokes from internal carotid artery occlusion: diagnostic and therapeutical implications. Stroke 1983; 14, 867-875.
130. Damasio, H. A computed tomographic guide to the identification of cerebral vascular territories. Arch. Neurol 1983; 40: 138-142.
131. Zülch, K. J. U. Ber die Entstehung und Lokalisation der Hirninfarkte. Zbliz. Neurochir 1961; 21, 158-178.
132. Kimura K, Kazui S, Minematsu K, et al. for the Japan Multicenter Stroke Investigator's Collaboration. Analysis of 16, 922 patients with acute ischaemic stroke and transient ischaemic attack in Japan. A hospital-based prospective registration study. Cerebrovasc Dis 2004; 18: 47-56.
133. Furie KL, Homma S, Kistler JP. Cardiac diseases. In: Stroke: Pathophysiology, Diagnosis, and Management. 4th ed. Churchill Livingstone, New York, 2004: pp. 747-759.
134. Ekdahl CT, Kokaia Z, Lindvall O. Brain inflammation and adult neurogenesis: The dual role of microglia. Neuroscience 2008; 158: 1021-1029.
135. Welsh P, Lowe GD, Chalmers J, et al. Associations of proinflammatory cytokines with the risk of recurrent stroke. Stroke 2008; 39: 2226-2230.
136. Lambert MP, Sachais BS, Kowalska MA. Chemokines and thrombogenicity. Thromb Haemost 2007; 97: 722-729.
137. Fateh-Moghadam S, Htun P, Tomandl B, et al. Hyperresponsiveness of platelets in ischaemic stroke. Thromb Haemost 2007; 97: 974-978.
138. Licata G, Tuttolomondo A, Di Raimondo D, Corrao S, Di Sciacca R, Pinto A. Immuno-inflammatory activation in acute cardioembolic strokes in comparison with other subtypes of ischaemic stroke. Thromb Haemost. 2009 May; 101(5): 929-937.
139. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891.
140. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-1184.
141. Aukrust P, Halvorsen B, Yndestad A, et al. Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol 2008; 2: 1909-1919.
142. Nakase T, Yamazaki T, Ogura N, et al. The impact of inflammation on the pathogenesis and prognosis of ischaemic stroke. J Neurol Sci 2008; 271: 104-109.
143. Rincon F, Dhamoon M, Moon Y, et al. Stroke location and association with fatal cardiac outcomes. Northern Manhattan Study (NOMAS). Stroke 2008; 39: 2425-2431.
144. Barber M, Wright F, Stott DJ, et al. Predictors of early neurological deterioration after ischaemic stroke: a case-control study. Gerontology 2004; 50: 102-109.
145. Serena J, Rodríguez-Yáñez M, Castellanos M. Deterioration in acute ischaemic stroke as the target for neuroprotection. Cerebrovasc Dis 2006; 21 (Suppl 2): 80-88.
146. Lubart E, Leibovitz A, Baumoehl Y, et al. Progressing stroke with neurological deterioration in a group of Israeli elderly. Arch Gerontol Geriatr 2005; 41: 95-100.
147. Lynch JR, Blessing R, White WD, et al. Novel diagnostic test for acute stroke. Stroke 2004; 35: 57-63.
148. Lavados PM, Sacks C, Prina L, et al. Incidence, case-fatality rate, and prognosis of ischaemic stroke subtypes in a predominantly Hispanic-Mestizo population in Iquique, Chile (PISCIS project): a community based incidence study. Lancet Neurol 2007; 6: 140-148.
149. Vaitkevicius PV, Fleg JL, Engel JH, et al. Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation 1993; 88: 1456-1462.
150. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39: 10-15.
151. Lehmann ED, Watts GF, Gosling RG. Aortic distensibility and hypercholesterolaemia. Lancet 1992; 340: 1171-1172.
152. Lehmann ED, Gosling RG, Sonksen PH. Arterial wall compliance in diabetes. Diabet Med 1992; 9: 114-119.
153. Muxfeldt ES, Fiszman R, Castelpoggi CH, Salles GF. Ambulatory arterial stiffness index or pulse pressure: which correlates better with arterial stiffness in resistant hypertension? Hypertens Res 2008; 31(4): 607-613.
154. Gordin D, Rönnback M, Forsblom C, et al. Glucose variability, blood pressure and arterial stiffness in type 1 diabetes. Diabetes Res Clin Pract 2008; 80(3): e4-7.
155. Muxfeldt ES, Fiszman R, Castelpoggi CH, Salles GF. Ambulatory arterial stiffness index or pulse pressure: which correlates better with arterial stiffness in resistant hypertension? Hypertens Res 2008; 31(4): 607-613.
156. Gordin D, Rönnback M, Forsblom C, et al. Glucose variability, blood pressure and arterial stiffness in type 1 diabetes. Diabetes Res Clin Pract 2008; 80(3): e4-7.
157. Rahman S, Ismail AA, Ismail SB, Naing NN, Rahman AR. Early manifestation of macrovasculopathy in newly diagnosed never treated type II diabetic patients with no traditional CVD risk factors. Diabetes Res Clin Pract 2008; 80(2): 253-258.
158. Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM. Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol. 1998; 18(4): 535-541.
159. De Silva D, Woon FP, Chen C, et al. Profile and associations of central pulse wave velocity and central pulse pressure among ischemic stroke patients. Eur J Neurol 2008; 15: 196-198.
160. Tuttolomondo A, Di Sciacca R, Di Raimondo D, et al. Arterial stiffness indexes in acute ischemic stroke: relationship with stroke subtype. Atherosclerosis 2010; 211(1): 187-194.
161. Mahmud A, Feely J. Arterial Stiffness Is Related to Systemic Inflammation in Essential Hypertension Hypertension 2005; 46: 1118-1122.
162. De Silva DA, Woon FP, Gan HY, et al. Arterial stiffness, metabolic syndrome and inflammation amongst Asian ischaemic stroke patients. Eur J Neurol 2008; 15(8): 872.
163. Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. Immuneinflammatory markers and arterial stiffness indexes in subjects with acute ischemic stroke. Atherosclerosis 2010; 213(1): 311-318.
164. Zoppo G I, Ginis JM, Hallenback C, Iadecola X, Wang GZ. Feuerstein. Inflammation and stroke: putative role for cytokines, adhesion molecules and i-NOS in brain response to ischemia. Brain Pathol 2000; 10: 95-101.
165. Sotgiu S, Zanda B, Marchetti B, et al. Inflammatory biomarkers in blood of patients with acute brain ischemia. Eur J Neurol 2006; 13(5): 505-513.
166. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38: 581-587.
167. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008; 51: 161-167.
168. Abramson JL, Weintraub WS, Vaccarino V. Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension 2002; 39: 197-202.
169. Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 2004; 24: 969-974.
170. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 2005; 46: 1118-1122.
171. Mattace-Raso FU, van der Cammen TJ, van der Meer I, et al. Creactive protein and arterial stiffness in older adults: the Rotterdam Study. Atherosclerosis 2004; 176: 111-116.
172. Schnabel R, Larson MG, Dupuis J, et al. Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension. 2008; 51: 1651-1657
173. Bhagat K, Hingorani AD, Palacios M, Charles IG, Vallance P. Cytokineinduced venodilatation in humans in vivo: eNOS masquerading as iNOS. Cardiovasc Res 1999; 41: 754-764.
174. Lee SH, Choi S, Jung JH, Lee N. Effects of atrial fibrillation on arterial stiffness in patients with hypertension. Angiology 2000; 59(4): 459-463.
175. Samdani AF, Dawson TM, Dawson VL. Nitric oxide synthase in models of focal ischemia. Stroke 1997; 28(6): 1283-1288.
176. Kaji Y, Miyoshi T, Doi M, et al. Augmentation index is associated with B-type natriuretic peptide in patients with paroxysmal atrial fibrillation. Hypertens Res 2009; 32(7): 611-616.
177. Syrjänen J, Valtonen VV, Iivanainen M, Kaste M, Huttunen JK. Preceding infection as an important risk factor for ischaemic brain infarction in young and middle aged patients. Br Med J 1988; 296: 1156-1160.
178. Ameriso SF, Wong VLY, Quismorio FP, Fisher M. Immunohematologic characteristics of infection-associated cerebral infarction. Stroke 1991; 22: 1004-1009.
179. Grau AJ, Buggle F, Heindl S, et al. Recent infection as a risk factor for cerebrovascular ischemia. Stroke 1995; 26: 373-379.
180. Grau AJ, Buggle F, Steichen-Weihn C, et al. Clinical and biochemical analysis in infection-associated stroke. Stroke 1995; 26: 1520-1526.
181. Ameriso SF, Wong VLY, Quismorio FP, Fisher M. Immunohematologic characteristics of infection-associated cerebral infarction. Stroke 1991; 22: 1004-1009.
182. Macko RF, Ameriso SF, Gruber A, et al. Impairments of the protein C system and fibrinolysis in infection-associated stroke. Stroke 1996; 27: 2005-2011.
183. Paganini-Hill A, Lozano E, Fischberg G, et al. Infection and risk of ischemic stroke: differences among stroke subtypes. Stroke. 2003; 34(2): 452-457.
184. Tsai NW, Chang WN, Shaw CF, et al. Levels and value of platelet activation markers in different subtypes of acute non-cardioembolic ischemic stroke. Thromb Res 2009; 124(2): 213-218.
185. Cherian P, Hankey GJ, Eikelboom JW, et al. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke 2003; 34(9): 2132-2137.
186. Cha JK, Jeong MH, Jang JY, et al. Serial measurement of surface expressions of CD63, P-selectin and CD40 ligand on platelets in atherosclerotic ischemic stroke. A possible role of CD40 ligand on platelets in atherosclerotic ischemic stroke. Cerebrovasc Dis 2003; 16(4): 376-382
187. Iwamoto T, Kubo H, Takasaki M. Platelet activation in the cerebral circulation in different subtypes of ischemic stroke and Binswanger's disease. Stroke 1995; 26(1): 52-56.
188. Shah AB, Beamer N, Coull BM. Enhanced in vivo platelet activation in subtypes of ischemic stroke. Stroke 1985; 16(4): 643-647.
189. Oberheiden T, Blahak C, Nguyen XD, et al. Activation of platelets and cellular coagulation in cerebral small-vessel disease. Blood Coagul Fibrinolysis 2010; 21(8): 729-735.
190. Fornage M, Chiang YA, O'Meara ES, et al. Biomarkers of Inflammation and MRI-Defined Small Vessel Disease of the Brain: The Cardiovascular Health Study. Stroke 2008; 39(7): 1952-1959.
191. Kumar S, Caplan LR. Why identification of stroke syndromes is still important. Curr Opin Neurol 2007; 20(1): 78-82.